Hearing Loss
We received several pages in quick succession before we even saw the patient in the clinic. Audiology paged immediately after their visit to report that, Liza, a 6-year-old girl with high-risk neuroblastoma...
Adherence to Oral Anticancer Treatment: Priorities in Lymphoma and CLL
Advances in cancer treatment have been nothing short of breathtaking in recent years. Among the most important has been the advent of effective oral therapies, marking a significant change in the way many patients receive...
Immunotherapy Benefits Survival, Improves Safety, vs Platinum-Based Chemotherapy for PD-L1–Expressing NSCLC
Immunotherapy with pembrolizumab (Keytruda) improved overall survival compared with investigator’s choice of platinum-based chemotherapy as first-line treatment for patients with advanced non–small cell lung cancer...
Mobile and Sensor Technology May Lead to Reduced Symptoms of Head and Neck Cancer and Its Treatment
A randomized clinical trial evaluating the use of mobile and sensor technology to remotely monitor symptoms in patients receiving radiation therapy for head and neck cancer found that use of this technology reduced the severity of symptoms related to cancer and its treatment compared with usual care. According to...
Geriatric Assessment Improves Communication Between Oncologists and Older Patients
A federally funded randomized study demonstrated that use of geriatric assessment in the routine care of older adults with advanced cancer significantly improved doctor-patient communication about age-related concerns...
Michael Williams: Adherence to Oral Treatment in Lymphoma and CLL
Daniel Hayes on Leadership and Success in Academic Medicine
Rana McKay on Nivolumab Plus Ipilimumab in Advanced RCC
Lucas Dean: MRI in Detection of Clinically Significant Prostate Cancer
Padmanee Sharma on Challenges in Recognizing and Reporting IRAEs
More Top Stories
AACR and Cancer Research UK Form Alliance
The American Association for Cancer Research (AACR) in collaboration with Cancer Research UK (CRUK) are launching a new international alliance to stimulate discoveries in cancer research. The two organizations share the vision that significant progress against cancer could be facilitated by...
ASCO/CAP Clinical Practice Guideline Focused Update on HER2 Testing in Breast Cancer
As reported in the Journal of Clinical Oncology by Antonio C. Wolff, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, and colleagues, ASCO and the College of American Pathologists (CAP) have issued a clinical practice guideline focused update on HER2 testing in breast cancer....
Tai Chi for the Treatment of Insomnia in Breast Cancer Survivors
Underrecognized and inadequately managed, insomnia is a significant burden for many cancer survivors. Often persistent over several years following diagnosis and treatment, sleep problems negatively affect quality of life and elevate the risk of depression and anxiety. In this installment of The...
Adherence to Oral Anticancer Treatment: Priorities in Lymphoma and CLL
ADVANCES IN cancer treatment have been nothing short of breathtaking in recent years. Among the most important has been the advent of effective oral therapies, marking a significant change in the way many patients receive treatment and in the oversight required by the cancer care team. As with...
Study Finds Recent-Onset Type 2 Diabetes May Be Early Manifestation of Pancreatic Cancer
According to the American Cancer Society, pancreatic cancer is one of the most deadly cancers, with an overall 5-year survival rate of just 8%, mainly because the vast majority of patients, about 80%, are diagnosed at a late stage of disease. Research has shown that identification of high-risk ...
CheckMate 214: Nivolumab Plus Ipilimumab Improves Survival vs Sunitinib in Advanced Renal Cell Cancer
As reported in The New England Journal of Medicine by Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, the phase III CheckMate 214 trial has shown an overall survival advantage with nivolumab (Opdivo) plus ipilimumab (Yervoy) vs sunitinib (Sutent) in patients with...
EHA 2018: Tazemetostat in Relapsed or Refractory Follicular Lymphoma
Positive interim data were recently presented from an ongoing phase II study of tazemetostat—a potent, selective, orally available EZH2 inhibitor—as a monotherapy for patients with relapsed or refractory follicular lymphoma. The data, presented by Salles et al at the 23rd Annual...
Helena Margaret Earl, MBBS, PhD, on Early Breast Cancer: Results From the Persephone Trial
